Crohn’s disease is a chronic inflammatory disease of the gut, that is difficult to clinically manage because current therapies are only partially effective. This leads to sub-optimal treatment, extra-intestinal complications and for instance, cancer. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in Crohn’s Disease have been recently discovered and validated by our team. We aim to bring personalised treatment selection in Crohn’s Disease and other IMID to clinical practice to enhance treatment efficacy.
In this webinar, Prof. dr. Wouter de Jonge will discuss our work within our Horizon Europe funded “METHYLOMIC” project, zooming in on Crohn’s Disease. The consortium comprises eighteen participants consisting of clinical, epigenetic, and DNA diagnostics experts, patient organizations, and companies across nine countries to ensure effective communication and commitment to help ease the challenges of patients with Crohn’s disease, Rheumatoid Arthritis and Psoriasis.
Attend the webinar and receive 0.15 continuing education credits (CECs).
